每周股票复盘：海欣股份（600851）子公司药品通过一致性评价

Core Viewpoint - The recent approval of the "Vitamin B6 Injection" by Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. is expected to enhance market competitiveness, although it will not significantly impact the company's current operating performance [1][2]. Company Announcement Summary - Haixin Co., Ltd. reported a stock price of 7.01 yuan as of December 26, 2025, down 1.68% from the previous week [1]. - The stock reached a high of 7.24 yuan and a low of 7.00 yuan during the week [1]. - The company's current total market capitalization is 8.461 billion yuan, ranking 64th out of 151 in the chemical pharmaceutical sector and 2213th out of 5178 in the A-share market [1]. - The "Vitamin B6 Injection" has been approved by the National Medical Products Administration and is classified as a Class A drug under the national medical insurance and essential drug list, with an estimated sales volume of approximately 304 million yuan in public medical institutions for 2024 [1][2]. - The successful completion of the consistency evaluation for the generic drug is expected to improve product competitiveness [2].